Guardant Health Inc (GH) is a leading precision oncology company that provides non-invasive cancer diagnostics. The company leverages its proprietary liquid biopsy platform to analyze the genetic information in a patient's blood, enabling early detection and monitoring of cancer. The stock has been attracting attention from investors due to its strong technical indicators.

One of the key technical indicators for GH stock is the Relative Strength Index (RSI), which measures the momentum of the stock. A high RSI value indicates that the stock is overbought, while a low RSI value suggests that the stock is oversold. GH stock has been showing a moderate RSI value, indicating a balanced market sentiment.

Guardant Health  (GH) Technical Analysis

Learn about the technical analysis indicators for Guardant Health Inc (GH) stock, including RSI, ADX, MACD, ROC, STOCHRSI, WILLR. Understand the trends and patterns to make informed investment decisions. Stay ahead of the market with Guardant Health Inc technical analysis.

Guardant Health Inc (GH) Stock Technical Analysis - Indicators, RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. Guardant Health, Inc. has a research collaboration agreement with the Parker Institute for Cancer Immunotherapy to study the correlation between molecular cancer biomarkers and patient response to immunotherapy treatment across various types of cancer. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Guardant Health 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	52.51	Neutral	50.7%
auto_graphMACD	17.16	Neutral	795.4%
auto_graphCCI	-49.77	Neutral	90.0%
auto_graphADX	27.29	Neutral	-
auto_graphATR	27.01	Buy	-
auto_graphWILLR	-67.32	Neutral	64.2%
auto_graphROC	-15.14	Sell	620.3%
auto_graphSTOCHRSI	0.00	Buy	24.7%

Buy	2	-75.00%
Hold	5	-37.50%
Sell	1	-87.50%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Guardant Health (GH) Technical Analysis

Keep an eye on Guardant Health

Frequently Asked Questions

What are the technical signals for Guardant Health (GH) stock based on the last 30 days?

Take Your Investments to a Whole New Level